Markers of detection

Urologic Oncology: Seminars and Original Investigations

Volumn 25, Issue 4, 2007, Pages 344-347

  Messing, Edward ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Detection; Hematuria; Markers; Monitoring bladder cancer; Screening

Indexed keywords

TUMOR MARKER;

BLADDER CANCER; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CYSTOSCOPY; DISEASE MARKER; FLUORESCENCE IN SITU HYBRIDIZATION; HEMATURIA; HIGH RISK POPULATION; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; TRANSURETHRAL RESECTION;

ANTIGENS, NEOPLASM; HUMANS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 34447104135     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2007.05.012     Document Type: Review

References (22)

1. Vaidya A., Soloway M., Hawke C., et al. De Novo muscle invasive bladder cancer: Is there a change in trend?. J Urol 165 (2001) 47
2. Kaye K.W., and Lange P.H. Mode of presentation of invasive bladder cancer: Reassessment of the problem. J Urol 128 (1982) 31
3. Hopkins S.C., Ford K.S., and Soloway M.S. Invasive bladder cancer: Support for screening. J Urol 130 (1983) 61
4. Messing E.M., Madeb R., Young T., et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 107 (2006) 2173-2179
5. Messing E.M., Young T.B., Hunt V.B., et al. The significance of asymptomatic microhematuria in men age fifty and over: Findings of a home screening study using urinary dipsticks. J Urol 137 (1987) 919-922
6. Sarosdy M.F., Kahn P.R., Ziffer M.D., et al. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol 176 (2006) 44-47
7. Jocham D., Witjes F., Wagner S., et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: A prospective, phase III multicenter study. J Urol 174 (2005) 862-866
8. Grossman H.B., Soloway M., Messing E.M., et al. Surveillance of patients with a history of bladder cancer using a point-of-care proteomic assay. JAMA 295 (2006) 299-305
9. Lotan Y., and Roehrborn C.G. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the follow-up of patients with transitional cell carcinoma of the bladder: A decision analytical approach. J Urol 167 (2002) 75-79
10. Messing E.M., Kim K., Sharkey F., et al. Randomized prospective phase III trial of difluoromethylornithine versus placebo in preventing recurrence of completely resected low risk superficial bladder cancer. J Urol 175 (2006) 500-504
11. Fleshner N., Garland J., Moadel A., et al. Influence of smoking status on the disease-related outcomes of patients with tobacco associated transitional cell carcinoma of the bladder. Cancer 86 (1999) 2337-2345
12. Boman H., Hedelin H., Holmang S., et al. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J Urol 167 (2002) 80-83
13. Yossepowitch O., Herr H.W., and Donat S.M. Use of urinary biomarkers for bladder cancer surveillance: Patient perspectives. J Urol 177 (2007) 1277-1282
14. O'Donnell M.A., Lilli K., and Leopold C. Contemporary profile of superficial bladder cancer as revealed from an open-entry national multicenter study. J Urol 171 (2004) 75A
15. Messing E.M., Madeb R.R., Golijanin D., et al. Long-term outcome of hematuria home screening for bladder cancer. J Urol 175 (2006) 284
16. Messing E.M., Young T.B., Hunt V.B., et al. Home screening for hematuria: Results of a multi-clinic study. J Urol 148 (1992) 289-292
17. Messing E.M., Young T.B., Hunt V.B., et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 45 (1995) 387-397
18. Cohen R.A., and Brown R.S. Microscopic hematuria. NEJM 348 (2003) 2330-2338
19. Grossfeld G.D., Wolfe J.S., Litwin M.S., et al. Asymptomatic microscopic hematuria in adults: Summary of the AUA Best Practice Policy Recommendations. Am Fam Phys 63 (2001) 1145-1154
20. Messing E.M., and Valencourt A. Hematuria screening for bladder cancer. J Occup Med 32 (1990) 838-845
21. Hofland C.A., and Mariani A.J. Is cytology required for a hematuria evaluation?. J Urol 171 (2004) 324-326
22. Grossman H.B., Messing E.M., Soloway M., et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 293 (2005) 810-816